Latest news about Rekvina Laboratories
Rekvina Laboratories
54.93
-1.12(-2.00%)
Company Performance:
View Company Insights1D-2.00%
1M+40.34%
6M+77.37%
1Y0.00%
5Y0.00%
More news about Rekvina Laboratories
30Jun 26
Rekvina Labs open offer at ₹10 per share opens July 1
The open offer by acquirers Surbhit Mukesh Shah, Amit Mukesh Shah, and Dhruvalkumar Patel to acquire up to 28,90,100 equity shares of Rekvina Laboratories Limited opens on July 1, 2026, at ₹10 per share. The offer, representing 26% of the expanded share capital, closes on July 14, 2026, with Vivro Financial Services Private Limited as the Manager to the Offer. The Committee of Independent Directors deemed the price fair despite the market price being ₹37.45, while SEBI observations and material changes, including the addition of Dhruvalkumar Patel and disclosures on contingent liabilities and FIRs, have been incorporated.
22May 26
Rekvina FY26 Net Loss ₹25.47 Lacs, Revenue ₹126.54 Lacs
Rekvina Laboratories Limited reported a widened net loss of ₹25.47 lacs for FY26, compared to ₹13.71 lacs in the previous year, with revenue from operations reaching ₹126.54 lacs. For the quarter ended March 31, 2026, the net loss stood at ₹6.05 lacs on a revenue of ₹72.36 lacs. The Board approved the acquisition of Radiant Parenterals Limited for ₹4.63 crore and an increase in authorised share capital, subject to shareholder approvals.
11Apr 26
Rekvina Laboratories Discloses Voting Results for EGM on Capital Restructuring
Rekvina Laboratories Limited has disclosed official voting results for its Extra-Ordinary General Meeting held on April 10, 2026, showing unanimous approval of all six proposed resolutions by shareholders. The resolutions covered share capital increase, articles alteration, investment limits expansion, related party transactions, and preferential equity issuance for both cash and non-cash considerations, demonstrating strong shareholder support for the company's capital restructuring initiatives.
07Apr 26
Rekvina Laboratories Claims Exemption from Annual Secretarial Compliance Report for FY26
Rekvina Laboratories Limited has claimed exemption from the Annual Secretarial Compliance Report for FY26 under SEBI Regulation 15(2), which applies to listed entities with paid-up equity capital not exceeding Rs 10 crores and net worth not exceeding Rs 25 crores. The exemption covers multiple corporate governance provisions including regulations 17-27 and specific clauses under regulation 46 and Schedule V. The company has formally notified BSE of this exemption status through an official communication dated 06.04.2026.
06Apr 26
Rekvina Laboratories Submits Q4FY26 Dematerialisation Compliance Certificate to BSE
Rekvina Laboratories Limited filed its Q4FY26 dematerialisation compliance certificate with BSE on 06.04.2026, covering the period from 1st January, 2026 to 31st March, 2026. The certificate, prepared by registrar M/s. Purva Sharegistry India Pvt. Ltd, shows no dematerialisation activity during the quarter, with 'NIL' entries across all parameters including folio numbers, shareholder names, and certificate numbers. This regulatory filing under SEBI (Depositories and Participants) Regulations, 2018 ensures compliance with quarterly reporting requirements for listed companies.
25Mar 26
Rekvina Laboratories Open Offer: Detailed Public Statement Published for 26% Stake Acquisition
Three acquirers have published a detailed public statement for their mandatory open offer to acquire 28,90,100 equity shares (26% stake) of Rekvina Laboratories at ₹10 per share, following a share swap agreement to acquire Radiant Parenterals. The offer involves ₹2,89,01,000 consideration with escrow arrangements in place and is scheduled to run from May 14-27, 2026.
18Mar 26
Rekvina Laboratories Schedules EGM for April 10 to Approve Capital Restructuring
Rekvina Laboratories has formally notified shareholders of an extraordinary general meeting on April 10, 2026, to vote on increasing authorized share capital from ₹3.50 crore to ₹6 crore, acquiring 100% stake in Radiant Parenterals for ₹4.62 crore through share exchange, and issuing additional equity shares for cash consideration.
17Mar 26
Rekvina Laboratories Discloses Open Offer Public Announcement to BSE
Rekvina Laboratories Limited has formally disclosed to BSE Limited the receipt of a public announcement for an open offer by three acquirers - Surbhit Mukesh Shah, Amit Mukesh Shah, and Dhruvalkumar Patel. The offer seeks to acquire 28,90,100 equity shares at ₹10 per share, representing 26% of expanded share capital with total consideration of ₹2,89,01,000. The transaction was triggered by a share exchange agreement for acquiring Radiant Parenterals Limited, managed by Vivro Financial Services under SEBI regulations.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Zydus Life Science
Cipla
Laurus Labs
Aurobindo Pharma
Dr Reddys Laboratories
Lupin
Mankind Pharma
1,837.30
(-1.61%)
9,375.00
(+0.56%)
4,840.00
(-0.72%)
1,160.00
(+2.19%)
1,394.50
(+1.32%)
1,954.00
(+0.30%)
1,734.00
(+2.60%)
1,185.00
(+0.85%)
2,083.00
(-0.72%)
2,300.70
(+0.03%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
